AG
SRPT icon

Artal Group’s Sarepta Therapeutics SRPT Stock Holding History

Artal Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-200,000
Closed -$9.07M – 127
2017
Q3 		$9.07M Buy
200,000
+50,000
+33% +$2M 0.16% 48
2017
Q2 		$5.06M Sell
150,000
-50,000
-25% -$1.63M 0.09% 62
2017
Q1 		$5.92M Hold
200,000
– – 0.13% 56
2016
Q4 		$5.49M Hold
200,000
– – 0.12% 53
2016
Q3 		$12.3M Buy
+200,000
New +$6.05M 0.24% 33

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Artal Group's SRPT Position: Q4 2017 in Review

Artal Group sold out of Sarepta Therapeutics (SRPT) in Q4 2017, closing a stake of 200,000 shares — an estimated $9.07M sold.

Artal Group first reported a position in SRPT in Q3 2016 and held it in 5 quarters. The position peaked at $12.3M in Q3 2016. 254 funds tracked by Wall St. Rank hold SRPT as of Q4 2017.

  • Artal Group reported no remaining Sarepta Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Artal Group sold 200,000 Sarepta Therapeutics shares in Q4 2017, an estimated $9.07M.
  • Artal Group first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 5 quarters.
  • Artal Group's Sarepta Therapeutics position peaked at $12.3M in Q3 2016.
  • 254 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2017.

Based on Artal Group's 13F filing for Q4 2017, filed 9 Feb 2018.